Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
|
31203567 |
2019 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pancreatic cancer and melanoma related perceptions and behaviors following disclosure of CDKN2A variant status as a research result.
|
30992552 |
2019 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we show that in an area with low melanoma incidence, CDKN2A germline mutations in patients with melanoma and personal or family history of pancreatic cancer are mainly present in the setting of familial or multiple melanoma cases.
|
29543703 |
2018 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results indicated that p16 can be used as a cue signal for diagnosing advanced pancreatic cancer.
|
29254312 |
2018 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We examined the immediate and delayed psychological impact of returning a CDKN2A variant result that is associated with increased risk of pancreatic cancer and melanoma.
|
30999302 |
2018 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Comparing 3030 case patients with pancreatic cancer (43.2% female; 95.6% non-Hispanic white; mean age at diagnosis, 65.3 [SD, 10.7] years) with reference controls, significant associations were observed between pancreatic cancer and mutations in CDKN2A (0.3% of cases and 0.02% of controls; odds ratio [OR], 12.33; 95% CI, 5.43-25.61); TP53 (0.2% of cases and 0.02% of controls; OR, 6.70; 95% CI, 2.52-14.95); MLH1 (0.13% of cases and 0.02% of controls; OR, 6.66; 95% CI, 1.94-17.53); BRCA2 (1.9% of cases and 0.3% of controls; OR, 6.20; 95% CI, 4.62-8.17); ATM (2.3% of cases and 0.37% of controls; OR, 5.71; 95% CI, 4.38-7.33); and BRCA1 (0.6% of cases and 0.2% of controls; OR, 2.58; 95% CI, 1.54-4.05).
|
29922827 |
2018 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The most consistently mutated genes are <i>KRAS, CDKN2A, TP53</i>, and <i>SMAD4/DPC4</i> Study of familial PDAC has led to the recognition that a variety of defects in DNA repair genes can be associated with the emergence of pancreatic cancer.
|
28373361 |
2017 |
Pancreatic carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study reports on the conjugation of cytotoxic drugs to an aptamer previously described by our group, the pancreatic cancer RNA aptamer P19.
|
28325302 |
2017 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the CDKN2A gene are associated with an increased risk of malignant melanoma and pancreatic cancer.
|
27804060 |
2017 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The combination of mutant KRAS with a single inactivating TP53, SMAD4 or CDKN2A mutation in genetically engineered mouse models (GEMMs) showed that these mutations exert different synergistic effects in PC.
|
28475592 |
2017 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although it is well known that CDKN2A mutations confer an increased risk for melanoma and pancreatic carcinoma, the association with an increased risk for nerve sheath tumours and other tumour types is under-recognized.
|
26876133 |
2016 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we observed a novel association in a pleiotropic region that has been found to be of key relevance in the susceptibility to various types of cancer and diabetes suggesting that the CDKN2A/B locus could represent a genetic link between diabetes and pancreatic cancer risk.
|
27486979 |
2016 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have tested nanopore sequencing to detect a series of well-characterized SVs, including large deletions, inversions, and translocations that inactivate the CDKN2A/p16 and SMAD4/DPC4 tumor suppressor genes in pancreatic cancer.
|
26787508 |
2016 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The most extensively documented association is between CDKN2A germ line mutations and pancreatic cancer, and a cancer syndrome including cutaneous melanoma, uveal melanoma and mesothelioma has been proposed for BAP1 germ line mutations.
|
26337759 |
2016 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Also, ATM variants (n = 5) were only observed in CDKN2A- PC patients with a family history that included digestive system tumors.
|
27449771 |
2016 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The p16-Leiden germline variant in the CDKN2A gene is associated with a high risk of melanoma and pancreatic cancer.
|
25227142 |
2015 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The results strongly suggest that CDKN2A methylation is correlated with an increased risk of pancreatic cancer.
|
26338139 |
2015 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
No standard medical management guidelines exist for families with CDKN2A mutations; however, family history of melanoma and pancreatic cancer may warrant further discussion.
|
24652319 |
2014 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Studies of the molecular pathology of pancreatic cancer have revealed that activation of KRAS, overexpression of cyclooxygenase-2, inactivation of p16(INK4A) and loss of p53 activities occurred in pancreatic cancer.
|
25152585 |
2014 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results show that the clinical candidate AKT inhibitor MK-2206 promotes ARF nucleolar localization, reduced p53(mut) stability and increased sensitivity to ionizing radiation in a xenograft model of pancreatic cancer.
|
25071014 |
2014 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
This review presents current evidence regarding both senescence induction and escape with respect to pancreatic cancer, highlighting the key roles of p19ARF, p53, Rb and P16INK4a.
|
25461770 |
2014 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Increasing knowledge about the molecular pathogenesis of the disease has shown that genetic alterations, such as mutations of K-ras, and especially epigenetic dysregulation of tumor-associated genes, such as silencing of the tumor suppressor p16(ink4a), are hallmarks of pancreatic cancer.
|
24976721 |
2014 |
Pancreatic carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activated K-Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype.
|
22806240 |
2013 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, a subset of pancreatic cancer is attributable to known inherited cancer predisposition syndromes, including several hereditary breast cancer genes (BRCA1, BRCA2, and PALB2), CDKN2A, hereditary pancreatitis, hereditary nonpolyposis colorectal cancer, and Peutz-Jeghers syndrome.
|
22846737 |
2013 |
Pancreatic carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thus, dietary energy balance modulation impacts spontaneous pancreatic tumorigenesis induced by mutant Kras and Ink4a deficiency, the most common genetic alterations in human pancreatic cancer.
|
23980075 |
2013 |